Pioglitazone and bladder cancer - Authors' reply

The Lancet

Volumn 378, Issue 9802, 2011, Pages 1544-1545

  Erdmann, Erland ^a   Dormandy, John A ^b   Massi Benedetti, Massimo ^c   Spanheimer, Robert ^d  

^a UNIVERSITY OF COLOGNE   (Germany)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c UNIVERSITY OF PERUGIA   (Italy)

^d TAKEDA PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE; PLACEBO; RIMONABANT; SIBUTRAMINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA;

ACUTE CORONARY SYNDROME; BLADDER CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; FRACTURE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LEG AMPUTATION; LEG REVASCULARIZATION; LETTER; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SILENT MYOCARDIAL INFARCTION; STROKE; CORONARY ARTERY DISEASE; DRUG POTENTIATION; FEMALE; MALE; NOTE;

CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MYOCARDIAL INFARCTION; PPAR GAMMA; STROKE; THIAZOLIDINEDIONES;

EID: 80155132326     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61664-4     Document Type: Letter

References (9)

1. Takeda Pharmaceuticals Actos (pioglitazone hydrochloride) tablets: US prescribing information http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2011/021073s035lbl.pdf (accessed July 26, 2011).
2. Takeda Pharmaceuticals Actos: summary of product characteristics http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/ human/000285/WC500021386.pdf (accessed July 26, 2011).
3. S Suzuki, LL Arnold, KL Pennington et al. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat Toxicol Sci 113 2010 349 357
4. JA Dormandy, B Charbonnel, DJ Eckland on behalf of the PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 366 2005 1279 1289 (Pubitemid 41416583)
5. J Dormandy, M Bhattacharya, AR van Troostenburg de Bruyn Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive Drug Saf 32 2009 187 202
6. JD Lewis, A Ferrara, T Peng et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study Diabetes Care 34 2011 916 922
7. E Mannucci, M Monami, C Lamanna, GF Gensini, N Marchionni Pioglitazone and cardiovascular risk: a comprehensive meta-analysis of randomized clinical trials Diabetes Obes Metab 10 2008 1221 1238
8. E Erdmann, R Wilcox Pioglitazone and mechanisms of CV protection QJM 103 2010 213 228
9. European Medicines Agency European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer http://www.ema.europa.eu/docs/en-GB/document-library/Press- release/2011/07/WC500109176.pdf (accessed Aug 1, 2011).